Liquidia Corporation (LQDA) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

65/ 100

GoAI Score

Buy

Valuation

87

Deep Value

Sentiment

47

Mixed

Risk

37

Moderate Risk

Momentum

71

Gaining

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Industry: Medical - Pharmaceuticals
Sector: Healthcare
Headquarters: US
CEO: Roger A. Jeffs
Listed since: Jul 26, 2018
Employees: 216

Market position

Day range

Current $28.02

$26.34$29.35

52-week range

Current $28.02

$21.94$93.61

Open: $26.60
Previous close: $26.68
Volume: 5.23M; 2.15× average
Average volume: 2.43M; Average daily volume
Market cap: 2.49B USD
Beta: 0.54; Market reference 1
50-day average: $68.4304; -59.05% below average
200-day average: $54.0849; -48.19% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 2.98B USD
P/E (TTM): 17.86×
P/B (TTM): 12.77×
P/S (TTM): 5.53×
EV / EBITDA: -68.84×
Earnings yield: -2.32%
Free cash flow yield: -1.35%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 92.48%
Operating margin: 37.39%
Net margin: 30.74%
Return on equity: -154.03%
Return on assets: -21.02%
Return on invested capital: -20.46%

Financial health

Debt / equity: 0.66×
Current ratio: 1.4×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

158.32M USD+1031.18%

Operating income

−51.38M USD+57.64%

Net income

−68.92M USD+47.14%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	158.32M USD	14M USD	17.49M USD	15.94M USD	12.85M USD
Cost of goods sold	13.24M USD	5.88M USD	2.89M USD	2.86M USD	3.02M USD
Gross profit	145.08M USD	8.12M USD	14.6M USD	13.08M USD	9.83M USD
Research and development	39.28M USD	47.84M USD	43.24M USD	19.44M USD	20.52M USD
Selling, general, and administrative	157.18M USD	81.57M USD	44.74M USD	32.41M USD	23.11M USD
Operating expenses	196.45M USD	129.41M USD	87.98M USD	51.85M USD	43.63M USD
Interest income	6.62M USD	7.65M USD	3.47M USD	1.09M USD	33K USD
Interest expense	24.17M USD	12.49M USD	6.27M USD	2.34M USD	762K USD
Depreciation and amortization	1.53M USD	2.2M USD	2.18M USD	3.65M USD	5.61M USD
Operating income	−51.38M USD	−121.29M USD	−73.38M USD	−38.77M USD	−33.8M USD
Net income	−68.92M USD	−130.39M USD	−78.5M USD	−41.02M USD	−34.58M USD

Company facts updated Oct 9, 2026.

Earnings

EPS beat rate: 36%; 4 beats, 6 misses, 1 met estimate
Average EPS surprise: +3.46%; 11 comparable reports
Latest EPS result: 0.74; Estimate 0.7 · Beat by 5.71%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$83.20

196.93% upside

Past 12 months12-month forecastHigh $130Average $83.20Low $30.00

Recent analyst actions

7 institutions

Raymond JamesupgradeOutperformStrong BuyAug 19, 2024

Ladenburg ThalmannmaintainBuyDec 21, 2023

WedbushmaintainUnderperformDec 21, 2023

LQDA news

globenewswire.comOct 8, 2026

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Liquidia Corporation (LQDA)

A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations A reported 57% plunge followed a court…

Read source

gurufocus.comOct 7, 2026

LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law

[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv

Read source

businesswire.comOct 7, 2026

LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.

Read source

globenewswire.comOct 7, 2026

LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Liquidia (LQDA) To Contact Him Directly To Discuss Their Options

Read source

globenewswire.comOct 6, 2026

LIQUIDIA CORPORATION INVESTIGATION: LQDA Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). The investigation concerns…

Read source

prnewswire.comOct 6, 2026

LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation

A court finding that Yutrepia infringed two valid claims of United Therapeutics' '327 patent has put the drug's PH-ILD indication and broader availability at risk. SueWallSt notifies investors of a pending investigation…

Read source